NasdaqGS - Delayed Quote • USD
Relmada Therapeutics, Inc. (RLMD)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -0.85 | -0.88 | -3.06 | -2.36 |
| Low Estimate | -0.92 | -1 | -3.8 | -4.12 |
| High Estimate | -0.75 | -0.75 | -2.61 | -1.6 |
| Year Ago EPS | -0.87 | -0.84 | -3.28 | -3.06 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 5 | 5 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.89 | -0.9 | -0.91 | -0.83 |
| EPS Actual | -0.87 | -0.84 | -0.73 | -0.84 |
| Difference | 0.02 | 0.06 | 0.18 | -0.01 |
| Surprise % | 2.20% | 6.70% | 19.80% | -1.20% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.85 | -0.88 | -3.06 | -2.36 |
| 7 Days Ago | -0.85 | -0.88 | -3.06 | -2.36 |
| 30 Days Ago | -0.85 | -0.88 | -3.06 | -2.36 |
| 60 Days Ago | -0.97 | -0.78 | -2.64 | -2.61 |
| 90 Days Ago | -0.97 | -0.78 | -2.53 | -2.59 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | RLMD | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 2.30% | -- | -- | 5.40% |
| Next Qtr. | -4.80% | -- | -- | 10.90% |
| Current Year | 6.70% | -- | -- | 4.50% |
| Next Year | 22.90% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 10.94% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | Mizuho: Buy to Buy | 6/15/2023 |
| Maintains | SVB Leerink: Outperform | 1/23/2023 |
| Downgrade | Goldman Sachs: Buy to Neutral | 10/14/2022 |
| Downgrade | Guggenheim: Buy to Neutral | 10/14/2022 |
| Downgrade | Oppenheimer: Outperform to Perform | 10/13/2022 |
| Maintains | Goldman Sachs: Buy | 9/23/2022 |
Related Tickers
LRMR Larimar Therapeutics, Inc.
6.44
+1.74%
BCTXW BriaCell Therapeutics Corp.
0.9375
+0.27%
ANEB Anebulo Pharmaceuticals, Inc.
2.7036
+1.26%
CLRB Cellectar Biosciences, Inc.
3.0300
+0.33%
VRCA Verrica Pharmaceuticals Inc.
6.87
+3.31%
INZY Inozyme Pharma, Inc.
4.4400
+2.54%
MDNAF Medicenna Therapeutics Corp.
1.8200
+30.00%
MREO Mereo BioPharma Group plc
2.7400
-2.49%
RPHM Reneo Pharmaceuticals, Inc.
1.6700
+1.21%
LIFE aTyr Pharma, Inc.
1.5700
-1.57%